Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Integrated molecular analysis reveals complex interactions between genomic and epigenomic alterations in esophageal adenocarcinomas.

Peng D, Guo Y, Chen H, Zhao S, Washington K, Hu T, Shyr Y, El-Rifai W.

Sci Rep. 2017 Jan 19;7:40729. doi: 10.1038/srep40729.

2.

Promoter hypermethylation of Wnt inhibitory factor-1 in patients with lung cancer: A systematic meta-analysis.

Zheng Y, Li X, Jiang Y, Xu Y, Song B, Zhou Q, Liang X, Yang X.

Medicine (Baltimore). 2016 Dec;95(49):e5433. Review.

3.

Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells.

Liu YZ, Zhang L, Roy-Engel AM, Saito S, Lasky JA, Wang G, Wang H.

Gene. 2017 Feb 20;602:16-23. doi: 10.1016/j.gene.2016.11.028.

PMID:
27866042
4.

Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis.

Jin J, Zhan P, Qian H, Wang X, Katoh M, Phan K, Chung JH, Lv T, Song Y; Written on behalf of the AME Lung Cancer Collaborative Group..

Transl Lung Cancer Res. 2016 Aug;5(4):436-42. doi: 10.21037/tlcr.2016.08.08.

5.
6.

Frizzled-7 promoter is highly active in tumors and promoter-driven Shiga-like toxin I inhibits hepatocellular carcinoma growth.

Xu H, Gong L, Xia Y, Qu L, Li Q, Pang L, Si J, Li Z.

Oncotarget. 2015 Nov 24;6(37):39908-23. doi: 10.18632/oncotarget.5516.

7.

Idiopathic pulmonary fibrosis and cancer: do they really look similar?

Vancheri C.

BMC Med. 2015 Sep 24;13:220. doi: 10.1186/s12916-015-0478-1.

8.

Platelet-derived Wnt antagonist Dickkopf-1 is implicated in ICAM-1/VCAM-1-mediated neutrophilic acute lung inflammation.

Guo Y, Mishra A, Howland E, Zhao C, Shukla D, Weng T, Liu L.

Blood. 2015 Nov 5;126(19):2220-9. doi: 10.1182/blood-2015-02-622233.

9.

Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.

Nakata A, Yoshida R, Yamaguchi R, Yamauchi M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M, Kimura T, Nokihara H, Higashiyama M, Kondoh K, Nishihara H, Tojo A, Yano S, Miyano S, Gotoh N.

Sci Rep. 2015 Aug 13;5:13076. doi: 10.1038/srep13076.

10.

Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers.

Wei C, Peng B, Han Y, Chen WV, Rother J, Tomlinson GE, Boland CR, Chaussabel D, Frazier ML, Amos CI.

Fam Cancer. 2015 Jun;14(2):297-306. doi: 10.1007/s10689-014-9758-8. Erratum in: Fam Cancer. 2015 Jun;14(2):307. Chaussabel, Marc [corrected to Chaussabel, Damien].

11.

Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness.

Gong X, Yi J, Carmon KS, Crumbley CA, Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT, Liu QJ.

Oncogene. 2015 Sep 3;34(36):4692-701. doi: 10.1038/onc.2014.417.

12.

S-Adenosylmethionine and methylthioadenosine inhibit β-catenin signaling by multiple mechanisms in liver and colon cancer.

Li TW, Peng H, Yang H, Kurniawidjaja S, Panthaki P, Zheng Y, Mato JM, Lu SC.

Mol Pharmacol. 2015 Jan;87(1):77-86. doi: 10.1124/mol.114.095679.

13.

Wnt signaling pathway pharmacogenetics in non-small cell lung cancer.

Stewart DJ, Chang DW, Ye Y, Spitz M, Lu C, Shu X, Wampfler JA, Marks RS, Garces YI, Yang P, Wu X.

Pharmacogenomics J. 2014 Dec;14(6):509-22. doi: 10.1038/tpj.2014.21.

14.

Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin.

Kafka A, Tomas D, Beroš V, Pećina HI, Zeljko M, Pećina-Šlaus N.

Int J Mol Sci. 2014 Jun 13;15(6):10635-51. doi: 10.3390/ijms150610635.

15.

The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics.

Sheikh A, Niazi AK, Ahmed MZ, Iqbal B, Anwer SM, Khan HH.

Hered Cancer Clin Pract. 2014 Apr 22;12(1):13. doi: 10.1186/1897-4287-12-13.

16.

Barrier function of airway tract epithelium.

Ganesan S, Comstock AT, Sajjan US.

Tissue Barriers. 2013 Oct 1;1(4):e24997. doi: 10.4161/tisb.24997. Review.

17.

Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.

Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M.

Genes Dev. 2014 Mar 15;28(6):561-75. doi: 10.1101/gad.233627.113.

18.

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.

PLoS One. 2013 Nov 15;8(11):e80885. doi: 10.1371/journal.pone.0080885.

19.

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N.

PLoS One. 2013 Nov 4;8(11):e78398. doi: 10.1371/journal.pone.0078398.

20.

Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt/β-catenin signaling pathway.

Lee SH, Zhu C, Peng Y, Johnson DT, Lehmann L, Sun Z.

J Biol Chem. 2013 Dec 13;288(50):35913-24. doi: 10.1074/jbc.M113.529727.

Items per page

Supplemental Content

Support Center